Neurodegenerative Alzheimer-like Pathology in PDAPP 717V → F Transgenic Mice
- 124 Downloads
Predominant pathological hallmarks of Alzheimer’s (AD) include the region-specific deposition of β amyloid (Aβ) plaques, vascular amyloidosis, and a number of distinct neurodegenerative changes. These involve the formation of dystrophic neurites and neuritic plaques, cytoskeletal alterations, and synaptic and neuronal loss. Astrocytosis and microgliosis are also evident in affected brain regions. Transgenic (tg) mice overexpressing a mutant form of the β-amyloid precursor protein (APP 717 V→ F) develop several of these pathologies in an age- and region-dependent manner similar to AD. Aβ plaques in the transgenic mouse share many of the tinctorial and immunohistochemical properties of AD plaques, including the relative distribution of AβX-40 and AβX-42 isoforms and the presence of other plaque-associated proteins. Initial findings using immunoassays specific to unique forms of APP and Aβ suggest that APP levels do not dramatically change with increasing age in the mouse brains, and that region-specific variations in APP metabolism, local factors or deficits in distinct populations of neurons account for the deposition of brain Aβ. The PDAPP mouse is a relevant and efficient model system to identify mechanistic properties of the disease process and offers novel opportunities to test potential therapeutics.
KeywordsDown Syndrome Senile Plaque Neuritic Plaque Dystrophic Neurites Neurobiol Aging
Unable to display preview. Download preview PDF.
- Asian PS, Davis KL (1994) Inflammatory mechanisms in Alzheimer’s disease: implications for therapy. Am J Psych 151: 1105 – 1113Google Scholar
- Cotman CW, Cummings BJ, Whitson JS (1991) The role of misdirected plasticity in plaque biogenesis and Alzheimer’s disease pathology. In: Growth factors and Alzheimer’s disease. Hefti F, Brachet P, Will B, Christen Y (eds) Alzheimer’s disease and related conditions. Springer-Verlag, Heidelberg, pp. 222 – 233Google Scholar
- Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie R, Guido T, Hagopian S, Johnson-Wood K, Khan I, Lee M, Leibowitz P, Liebergurb I, Little S, Masliah E, McConlogue L, Montoya Azvala M, Mucke L, Paganini L, Penniman E, Power M, Schenk D, Seubert P, Snyder B, Soriano F, Tan H, Vitale J, Wadsworth S, Wolozin B, Zhao J (1995) Development of neuropathology similar to Alzheimer’s disease in transgenic mice overexpressing the 717V→F β-amyloid precursor protein. Nature 373: 523 – 527PubMedCrossRefGoogle Scholar
- Perlmutter LS, Scott SA, Chui HC (1991) The role of microglia in the cortical neuropathology of Alzheimer disease. Bull Clin Neurosci 56: 120 – 130Google Scholar
- Selkoe DJ, Bell DS, PodlinskyMB, Price DL, Cork LC (1987) Conservation of brain amyloid in aged mammals and humans with Alzheimer’s disease. Science 235: 873 – 877Google Scholar
- Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, Sinha S, Schlossmacher M, Whaley J, Swindlehurst C, McCormack R, Wolfert F, Selkow D, Lieberburg I, Schenk D (1992) Isolation and quantification of soluble Alzheimer’s β-peptide from biological fluids. Nature 359: 325 – 327PubMedCrossRefGoogle Scholar
- Su JH, Cummings BJ, Cotman CW (1994) Early phosphorylation of tau in Alzheimer’s disease occurs at Ser-202 and is preferentially located within neurites. Neuro Report 5: 2358 – 2362Google Scholar
- Terry RD, Masliah E, Hansen LA (1994) Structural basis of the cognitive alterations in Alzheimer’s disease. In: Terry RD, Katzman R, Bick KL (eds). Alzheimer’s disease. Raven Press, New York pp. 179 – 196Google Scholar
- Yamaguchi H, Harai S, Morimatsu M, Shoji M, Ihara Y (1988) A variety of cerebral amyloid deposits in the brains of Alzheimer-type dementia demonstrated by β protein immunostaining. Acta Neuropathol 541 – 549Google Scholar